Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Prowess-shock trial: a protocol overview and perspectives.

Silva E, de Figueiredo LF, Colombari F.

Shock. 2010 Sep;34 Suppl 1:48-53. doi: 10.1097/SHK.0b013e3181e7e97b. Review.

PMID:
20523271
2.

Corticosteroids and human recombinant activated protein C for septic shock.

Colin G, Annane D.

Clin Chest Med. 2008 Dec;29(4):705-12, x. doi: 10.1016/j.ccm.2008.06.009. Review.

PMID:
18954704
3.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

4.

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.

PMID:
18158435
5.

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL.

J Crit Care. 2007 Jun;22(2):142-52. Epub 2007 Jan 31.

PMID:
17548026
6.

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

Crit Care. 2008;12(5):R117. doi: 10.1186/cc7011. Epub 2008 Sep 11.

7.

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

Crit Care Med. 2005 May;33(5):952-61.

PMID:
15891319
8.

[PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].

Cobas Meyer M, Langenfeld H, Rossaint R, Sablotzki A.

Anaesthesist. 2006 Jun;55 Suppl 1:16-23. Review. German.

PMID:
16680442
9.
10.

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

McCoy C.

Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.

PMID:
15500421
11.

Drotrecogin alfa (activated) in adults with septic shock.

Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group.

N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.

PMID:
22616830
12.

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group.

Crit Care Med. 2001 Mar;29(3):503-10.

PMID:
11373411
13.

Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.

Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R.

Crit Care Med. 2007 Jan;35(1):118-26.

PMID:
17095947
14.

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

PMID:
16895513
15.

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. doi: 10.1186/cc6156. Review.

16.

A prospective, observational study of Xigris Use in the United States (XEUS).

Steingrub JS, Cheatham ML, Woodward B, Wang HT, Effron MB; XEUS Investigators.

J Crit Care. 2010 Dec;25(4):660.e9-16. doi: 10.1016/j.jcrc.2010.03.009.

PMID:
20435433
17.

[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].

Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P.

Gac Sanit. 2004 Jan-Feb;18(1):50-7. Spanish.

18.

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.

PMID:
17973539
19.

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

Crit Care Med. 2004 Nov;32(11):2207-18.

PMID:
15640632
20.

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.

PMID:
12544987

Supplemental Content

Support Center